Rahul Baxi can't catch a break these days. A waiting room for a diabetologist based in Mumbai Bosure-Story every time someone enters his clinic. “Sir Wajan Where Karne Ki Nayi Davai Aai Hai, Woh Shura Kar Sakte Hain Kya, weight loss to Liy?”.
India has officially begun with a new weight loss injection of 16,000 ₹ per month.
“This is not a magic injection for all,” Dr. Baxi quickly explains X.
This injection that causes all buzzing is Mounjaro (Tirzepatide), just presented by the pharmaceutical giant Eli Lilly in India, in front of Nordisk's Weg's rival. Sold primarily for diabetes and significant weight loss, the price for 4,375 GBP for 5 mg bottle, which cost patients about 16,000 GBP per month – throughout India, but compared to US costs over $ 1,000 per month.
Dr. Manisha ARORA, director of the Hospital Birla Hospital, explains her attraction in the Indian Express: Mounjaro story mimics two hormones-GLP-1 and GIP-cow to eat, stabilize blood sugar and slow digestion, leading to an impressive weight loss of up to 20 kg in 72 weeks.
But this powerful injection is not without risks. Dr. The arra clearly warns: “Common side effects are gastrointestinal problems such as nausea, vomiting, diarrhea and sour reflux. In some cases, severe diarrhea may lead to dehydration and acute kidney damage.”
A rapid weight loss can also lead to bile stones inflammation and gallbladder inflammation.
Who is the ideal candidate? Adults fight with diabetes 2. Type, those who significantly overweight or individuals with insulin resistance do not respond to other treatments. However, the drug is beyond the limits for pregnant women, children, type 1 diabetics, individuals with a history of thyroid cancer, pancreatitis or serious gastrointestinal disorders.
Dissemination is not surprising due to epozicity and diabetes of India's epidemic.
Cases of diabetes could increase to 124 million by 2045, and almost a quarter of Indian adults are overweight or obese.
